Deals
Apogee’s pipeline in a product drug zumilokibart achieved significant disease clearance in a mid-stage atopic dermatitis trial, but investors were miffed by a royalty financing deal with Blackstone.
FEATURED STORIES
European pharma companies splashed billions of dollars into the U.S. biopharma sector in a matter of days, but there are differing views on whether the activity represents the rise of a new buyer class or a quirk of timing.
After years of suffering from a bear market and more than 14 months of geopolitical turmoil shaking the macroenvironment, biotech appears to be moving on.
With six acquisitions already this year, Eli Lilly’s business development shows no signs of stopping as executives make good on a promise to spend their GLP-1 gains.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Allergan is a good example of how many mergers and acquisitions over a very short period of time created a large, international company.
WuXi AppTec will acquire a global clinical-stage contract research company, ResearchPoint Global, of Austin, Texas.
Pfizer has increased its stake in Rhythm Pharmaceuticals.
Sachem Head Capital Management is pushing for that company to break up into small entities in order to increase shareholder value.
Amneal and Impax are combining into a new entity that is expected to have the fifth largest generics business in the United States.
The approval has made Flexion an even bigger target of acquisition rumors.
In a filing with the SEC,Orexigen indicated that it may not have enough funds to continue operating.
